Blair William & Co. IL increased its position in Insulet Co. (NASDAQ:PODD) by 4.4% in the third quarter, HoldingsChannel reports. The firm owned 16,340 shares of the medical instruments supplier’s stock after purchasing an additional 692 shares during the quarter. Blair William & Co. IL’s holdings in Insulet were worth $1,731,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Chicago Equity Partners LLC acquired a new position in Insulet in the second quarter worth about $375,000. Oppenheimer Asset Management Inc. acquired a new position in Insulet in the second quarter worth about $300,000. Paloma Partners Management Co boosted its stake in Insulet by 2,104.4% in the second quarter. Paloma Partners Management Co now owns 168,699 shares of the medical instruments supplier’s stock valued at $14,458,000 after acquiring an additional 161,046 shares during the period. OppenheimerFunds Inc. boosted its stake in Insulet by 26.6% in the second quarter. OppenheimerFunds Inc. now owns 791,702 shares of the medical instruments supplier’s stock valued at $67,848,000 after acquiring an additional 166,585 shares during the period. Finally, State of Wisconsin Investment Board boosted its stake in Insulet by 78.7% in the second quarter. State of Wisconsin Investment Board now owns 71,482 shares of the medical instruments supplier’s stock valued at $6,126,000 after acquiring an additional 31,482 shares during the period.

Shares of NASDAQ PODD opened at $83.96 on Friday. The company has a debt-to-equity ratio of 2.95, a current ratio of 4.58 and a quick ratio of 3.99. The company has a market cap of $4.88 billion, a PE ratio of -182.52 and a beta of 1.70. Insulet Co. has a 12-month low of $67.43 and a 12-month high of $108.90.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, November 1st. The medical instruments supplier reported $0.03 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.02 by $0.01. The business had revenue of $151.10 million during the quarter, compared to the consensus estimate of $148.82 million. Insulet had a negative return on equity of 7.63% and a negative net margin of 2.54%. The business’s revenue was up 24.1% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.04) earnings per share. On average, analysts predict that Insulet Co. will post -0.05 earnings per share for the current year.

A number of brokerages have commented on PODD. Zacks Investment Research downgraded Insulet from a “buy” rating to a “hold” rating in a research note on Friday, August 17th. BidaskClub downgraded Insulet from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, September 25th. Oppenheimer set a $100.00 target price on Insulet and gave the company a “hold” rating in a research note on Friday, November 2nd. Morgan Stanley lifted their target price on Insulet from $96.00 to $105.00 and gave the company an “equal weight” rating in a research note on Thursday, October 11th. Finally, Leerink Swann restated an “outperform” rating and issued a $130.00 target price on shares of Insulet in a research note on Tuesday, September 11th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $101.44.

In other news, SVP David Colleran sold 6,113 shares of the business’s stock in a transaction that occurred on Wednesday, November 14th. The stock was sold at an average price of $80.41, for a total transaction of $491,546.33. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Aiman Abdel-Malek sold 602 shares of the business’s stock in a transaction that occurred on Monday, October 15th. The stock was sold at an average price of $88.58, for a total value of $53,325.16. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 9,053 shares of company stock valued at $756,844. Insiders own 3.60% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Blair William & Co. IL Boosts Position in Insulet Co. (PODD)” was originally reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another website, it was illegally stolen and republished in violation of U.S. and international copyright law. The legal version of this article can be viewed at https://www.watchlistnews.com/blair-william-co-il-boosts-position-in-insulet-co-podd/2666730.html.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.

Further Reading: Diversification For Individual Investors

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Co. (NASDAQ:PODD).

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.